Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 4/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2946741 | 0.89 | DGAT1 (0.44) | DGAT1CTSKALDH1A1TDP1CA1 | |
| SCHEMBL18186430 | 0.89 | DGAT1 (0.34) | DGAT1CTSK | |
| SCHEMBL16445931 | 0.89 | DGAT1 (0.34) | DGAT1CTSK | |
| SCHEMBL20657046 | 0.89 | DGAT1 (0.34) | DGAT1CTSK | |
| SCHEMBL16885807 | 0.88 | DGAT1 (0.37) | DGAT1CTSKUSP2SMN1; SMN2TDP1 | |
| SCHEMBL3489322 | 0.86 | DGAT1 (0.36) | DGAT1CTSK | |
| SCHEMBL19216979 | 0.86 | DGAT1 (0.36) | DGAT1CTSK | |
| SCHEMBL1088416 | 0.86 | CTSK (0.38) | DGAT1CTSKELANE | |
| SCHEMBL19912070 | 0.84 | DGAT1 (0.34) | DGAT1CTSK | |
| SCHEMBL1088806 | 0.80 | CTSK (0.35) | DGAT1CTSKCA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358943-B1 | Method of synthesizing testosterone-based thiazolidinone derivatives | IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (SA) | 2025-07-15 | — | — | US | claimed |
| CN-114149444-B | Method for synthesizing 2,3,6,7-anthracene tetracarboxylic dianhydride | 常州市阳光药业有限公司 | 2022-11-15 | — | — | CN | claimed |
| CN-114149444-A | Synthesis method of 2,3,6, 7-anthracene tetracarboxylic dianhydride | 常州市阳光药业有限公司 | 2022-03-08 | — | — | CN | claimed |
| EP-4240433-B1 | MEDICAL SILICONE PRESSURE-SENSITIVE ADHESIVE COMPOSITION | ELKEM SILICONES SHANGHAI CO LTD (CN) | 2025-12-24 | — | — | EP | disclosed |
| US-20250352692-A1 | MEDICAL SILICONE PRESSURE-SENSITIVE ADHESIVE COMPOSITION | ELKEM SILICONES FRANCE SAS (FR) | 2025-11-20 | — | — | US | disclosed |
| US-12453800-B2 | Medical silicone pressure-sensitive adhesive composition | ELKEM SILICONES SHANGHAI CO., LTD. (CN) | 2025-10-28 | — | — | US | disclosed |
| US-12358943-B1 | Method of synthesizing testosterone-based thiazolidinone derivatives | IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (SA) | 2025-07-15 | — | — | US | disclosed |
| CN-119213094-A | Medical silicone pressure sensitive adhesive composition | 埃肯有机硅法国简易股份公司 | 2024-12-27 | — | — | CN | disclosed |
| US-12037459-B2 | Additive organopolysiloxane composition, curable composition, and film | DOW SILICONES CORPORATION | 2024-07-16 | — | — | US | disclosed |
| CN-117820323-A | Synthesis method of pyrazolone spiro-dihydropyrrole derivative | 安徽工程大学 | 2024-04-05 | — | — | CN | disclosed |
| US-20240009343-A1 | MEDICAL SILICONE PRESSURE-SENSITIVE ADHESIVE COMPOSITION | ELKEM SILICONES FRANCE SAS (FR) | 2024-01-11 | — | — | US | disclosed |
| WO-2003045384-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2003-06-05 | — | — | WO | disclosed |
| EP-1314426-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1045836-A1 | PYRIDONES AS SRC FAMILY SH2 DOMAIN INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999031066-A1 | PYRIDONES AS SRC FAMILY SH2 DOMAIN INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| WO-1998046652-A1 | SUBSTITUTED POLY(PHENYLENEVINYLENE)S AND POLY(NAPTHALENEVINYLENE)S | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-10-22 | — | — | WO | disclosed |
| US-5439516-A | Consists of an electron donating color forming organic compound, a heat activator and a color developer; used as recording material | NIPPON PAINT CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
| US-5140013-A | Shelf life; polymerization inhibition; nontoxic; side effects reduction | UNIVERSITE LAVAL (CA) | 1992-08-18 | — | — | US | disclosed |
| WO-1991008775-A2 | MALEIC ANHYDRIDE DERIVATIVES USED AS CONJUGATION AGENTS OF ANTI-TUMOR AGENTS ON DESIRED CARRIERS | UNIVERSITE LAVAL (CA) | 1991-06-27 | — | — | WO | disclosed |
| US-4764368-A | Acid-cleavable compound | DANA-FARBER CANCER INSTITUTE, INC. (US) | 1988-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358943-B1 | Method of synthesizing testosterone-based thiazolidinone derivatives | ERG28, CYP17A1, AR | DGAT1 3597/4885CTSK 4303/4885USP2 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.